scholarly journals Sedum emarginatum and its polysaccharide have a therapeutic effect on alcoholic liver disease in mice

2020 ◽  
Vol 9 (5) ◽  
pp. 308-316
Author(s):  
Gong Yuruo ◽  
◽  
Shi Dujuan ◽  
Wei Kevin Zhang ◽  
Xinzhou Yang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Mortality Rate ◽  
Mouse Model ◽  
Fatty Liver ◽  
Therapeutic Effect ◽  
Alcoholic Liver Disease ◽  
Liver Tissue ◽  
Alcoholic Hepatitis ◽  
Alcoholic Fatty Liver ◽  
Crude Polysaccharide

Objective: To explore the therapeutic effect of Sedum emarginatum (SE) and its polysaccharide on alcoholic liver disease. Methods: First, we ground fresh SE to obtain homogenate, and then test the effect of SE on a mouse model of acute alcoholic fatty liver disease (AFLD). Kunming female mice were given intragastric administration of alcohol once every 12 hours to induce AFLD, three times in total, and the mice received ethanol and SE at the same time. The mice were sacrificed 4 hours after the last alcohol administration, and serum and liver were collected for testing. We found that SE was effective and then carried out subsequent experiments. The dried SE powder was extracted under heating and reflux by different polar solvents: petroleum ether, ethyl acetate, methanol and water. The extracting solution were heat and concentrated to obtain an extract. The water part was purified to obtain polysaccharide. We tested the therapeutic effect of each part of SE in a mouse model of early alcoholic hepatitis (AH). Mice were given 5 g/kg of alcohol every 12 hours, a total of 9 times, and lipopolysaccharide (LPS) was injected intraperitoneally at the 36 h and 84 h. After 4 hours of the last gavage, the mice were sacrificed. The serum and liver tissue were used to tested relevant biochemical indexes. Results: SE had a certain reversal effect on the increase of serum triglycerides caused by alcohol, and it had a better effect on the accumulation of lipid droplets in liver tissues. Oil red O staining proved this result. In the second acute experiment, the mortality rate of the animal in the model group was 7/12, and the mortality rate in each treatment group was 1/8, 1/7, 4/8, and 1/8. In all parts, the crude polysaccharide did not significantly reverse the increase of serum triglyceride levels in early AH, but it could significantly alleviate the increase of inflammatory foci and steatosis in liver tissue. The transmission electron microscopy result indicates that the crude polysaccharide component has a certain protective effect on mitochondrial damage caused by alcohol. Conclusion: SE can reduce fatty liver and hyperlipidemia caused by alcohol, and its polysaccharide can reduce liver inflammation in the early alcoholic hepatitis by protecting mitochondron.

Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats

Phytomedicine ◽  
2021 ◽  
Vol 85 ◽  
pp. 153550
Author(s):  
Qiao-Ping Li ◽  
Yao-Xing Dou ◽  
Zi-Wei Huang ◽  
Han-Bin Chen ◽  
Yu-Cui Li ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Therapeutic Effect ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease

Cell Cycle ◽  
2012 ◽  
Vol 11 (10) ◽  
pp. 1918-1928 ◽  
Author(s):  
Erin K. Daugherity ◽  
Gabriel Balmus ◽  
Ahmed Al Saei ◽  
Elizabeth S. Moore ◽  
Delbert Abi Abdallah ◽  
...  
Keyword(s):  
Dna Damage ◽  
Liver Disease ◽  
Mouse Model ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Dna Damage Checkpoint ◽  
Alcoholic Fatty Liver ◽  
Checkpoint Protein ◽  
Hepatocellular Apoptosis ◽  
Alcoholic Fatty Liver Disease

scholarly journals Evaluation of Aroclor 1260 exposure in a mouse model of diet-induced obesity and non-alcoholic fatty liver disease

2014 ◽  
Vol 279 (3) ◽  
pp. 380-390 ◽  
Author(s):  
Banrida Wahlang ◽  
Ming Song ◽  
Juliane I. Beier ◽  
K. Cameron Falkner ◽  
Laila Al-Eryani ◽  
...  
Keyword(s):  
Liver Disease ◽  
Mouse Model ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Diet Induced Obesity ◽  
Alcoholic Fatty Liver Disease

Efficacy and Safety of a Fixed Combination of Glycyrrhizic Acid and Essential Phospholipids in Non-Alcoholic Fatty and Alcoholic Liver Disease: Results from Randomized Placebo-Controlled Trials

2021 ◽  
Vol 76 (6) ◽  
pp. 595-603
Author(s):  
Igor V. Maev ◽  
Alexey O. Bueverov ◽  
Artem V. Volnukhin
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Alcoholic Liver Disease ◽  
Fatty Liver Disease ◽  
Glycyrrhizic Acid ◽  
Fixed Combination ◽  
Efficacy And Safety ◽  
Alcoholic Fatty Liver ◽  
Essential Phospholipids ◽  
Alcoholic Fatty Liver Disease

Background. Drug treatment of non-alcoholic fatty and alcoholic liver disease remains an urgent, unsolved problem. Due to the commonality of many pathogenetic mechanisms and predictors of progression, a universal approach to the search for a therapeutic agent can be considered. Aims pooled analysis of the results of two multicenter, randomized, double-blind, placebo-controlled studies of a fixed combination of glycyrrhizic acid and essential phospholipids in two dosage forms to study its efficacy and safety in non-alcoholic fatty and alcoholic liver disease, in the presence and absence of predictors of disease progression. Methods. The pooled analysis included 180 patients with non-alcoholic fatty liver disease (Gepard study) and 120 patients with alcoholic liver disease (Jaguar study). Patients of the main group received a fixed combination of 5.0 g intravenous jet 3 times a week for the first 2 weeks; then 2 capsules 3 times a day for the next 10 weeks. Patients in the control group received placebo according to the same scheme. The total duration of treatment was 12 weeks in the Gepard study (1 course of stepwise therapy) and 24 weeks in the Jaguar study (2 courses of stepwise therapy). A comparative analysis of the efficacy and safety of a fixed combination and a placebo was carried out, in the presence and absence of predictors of progression, separately for each nosology and in a mixed sample. Results. In patients with non-alcoholic fatty and alcoholic liver disease who received the fixed combination, in contrast to the placebo group, there was a statistically more significant decrease in the level of biochemical markers of inflammation alanine aminotransferase, aspartate aminotransferase, adiponectin, and the value of the AktiTest index. There was no negative trend in the NAFLD fibrosis score; more significant positive dynamics of FibroTest is shown. Predictors of disease progression hyperglycemia, hyperlipidemia, age did not have a negative impact on the results in the study group. The efficacy of the study drug was noted in patients with non-alcoholic fatty liver disease and normal body weight; data were obtained indicating its possible effectiveness with a high activity of the inflammatory process associated with alcoholic liver damage. The frequency of adverse events in the study and control groups was comparable. Conclusions. Based on a generalized analysis of the results of two studies, promising directions for the study and use of a fixed combination of glycyrrhizic acid and essential phospholipids were identified: non-alcoholic fatty liver disease without obesity, alcoholic steatohepatitis of high activity (as an adjuvant); steatohepatitis of non-alcoholic and alcoholic etiology, combined with hyperglycemia and hyperlipidemia.

scholarly journals The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease

2020 ◽  
Vol 11 ◽  
Author(s):  
Silvana Y. Romero-Zerbo ◽  
María García-Fernández ◽  
Vanesa Espinosa-Jiménez ◽  
Macarena Pozo-Morales ◽  
Alejandro Escamilla-Sánchez ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Liver Disease ◽  
Mouse Model ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Fatty liver disease in children

2011 ◽  
Author(s):  
R. Mark Beattie ◽  
Anil Dhawan ◽  
John W.L. Puntis
Keyword(s):  
Liver Disease ◽  
Alcohol Consumption ◽  
Liver Injury ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Hepatitis ◽  
Alcoholic Fatty Liver ◽  
End Stage Liver Disease ◽  
End Stage ◽  
Alcoholic Fatty Liver Disease

Demographics 406Pathophysiology 406Differential diagnoses 407Presenting features 407Investigation 408Management 409Fatty liver disease is now increasingly recognized in children, particularly in the setting of obesity.The term non-alcoholic steatohepatitis (NASH) was first coined in 1980 by Ludwig to describe a pattern of liver injury in adults in which the liver histology was consistent with alcoholic hepatitis, but in whom significant alcohol consumption was denied. NASH can be considered as part of a broader spectrum of non-alcoholic fatty liver disease that extends from simple steatosis through steatohepatitis that is characterized by the potential to progress to fibrosis, cirrhosis and subsequent end stage liver disease....

scholarly journals Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease

2020 ◽  
Vol 5 ◽  
pp. 31-31
Author(s):  
Jose Altamirano ◽  
Qiaochu Qi ◽  
Sabina Choudhry ◽  
Mohamed Abdallah ◽  
Ashwani K. Singal ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Alcoholic Liver Disease ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Non Invasive ◽  
Alcoholic Fatty Liver Disease

Therapeutic Effect of Puerarin on Non-Alcoholic Rat Fatty Liver by Improving Leptin Signal Transduction through JAK2/STAT3 Pathways

2009 ◽  
Vol 37 (01) ◽  
pp. 69-83 ◽  
Author(s):  
Peiyong Zheng ◽  
Guang Ji ◽  
Zansong Ma ◽  
Tao Liu ◽  
Lianjun Xin ◽  
...  
Keyword(s):  
Signal Transduction ◽  
Liver Disease ◽  
Fatty Liver ◽  
Therapeutic Effect ◽  
Fatty Liver Disease ◽  
Receptor Expression ◽  
Male Rat ◽  
Group Model ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

In order to investigate the mechanism of the therapeutic effect of puerarin on non-alcoholic fatty liver disease, a non-alcoholic fatty disease male rat model was induced by a high fat diet, all rats were randomly divided into a blank group, model group, simavastatin group and puerarin group. After 4 weeks of drug treatment, the liver was slided to investigate pathological morphology. Elisa was used to measure the total cholesterol (TC), triglyeride (TG) in liver, and leptin content in serum. RT-PCR and Western blotting were employed to detect liver leptin mRNA receptor expression and P-JAK2, P-STAT3 expression levels in the liver respectively. The results showed that puerarin significantly decreased the TG, TC content in liver of the non-alcoholic fatty disease rats, ameliorated steatosis in liver, lowered liver inflammatory reaction, decreased leptin level in serum, and enhanced the expression of leptin receptor mRNA and P-JAK2/P-STAT3 level. All the results demonstrated that puerarin can exhibit therapeutic effect on non-alcoholic fatty liver disease by improving leptin signal transduction through JAK2/STAT3 pathways.

Sign in / Sign up

Export Citation Format

Share Document